Navigation Links
Perrigo Announces FDA Approval for Generic Version of NASACORT(R) AQ
Date:8/3/2009

ALLEGAN, Mich., Aug. 3 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that its partner Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) (previously Barr Laboratories Inc.) has received final approval from the U.S. Food and Drug Administration to market Triamcinolone Acetonide Nasal Spray containing a paragraph IV certification. Perrigo's partner Teva was the first applicant to file a complete ANDA with a Paragraph IV certification for NASACORT AQ. The product was developed at Perrigo.

Under the terms of a previously disclosed settlement, Teva will be able to market the ANDA product which is manufactured by Perrigo under license from Sanofi-Aventis commencing on June 15, 2011. Perrigo will share in the costs and benefits in Teva's marketing of the products under the agreement.

The product is the AB-rated equivalent to Sanofi - Aventis' Nasacort(R) AQ, indicated for the treatment of the nasal symptoms of seasonal and year round allergies in adults and children six years of age and older. Sales for the brand were approximately $305 million, according to Wolters Kluwer data for the twelve months ending June 2009.

Perrigo's Chairman and CEO Joseph C. Papa concluded, "This approval is a terrific example of Perrigo's strategic focus on developing challenging products in the extended topical categories. It further demonstrates our strategy to deliver quality affordable healthcare for generic prescriptions and over the counter products."

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) an
'/>"/>

SOURCE Perrigo Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Perrigo Receives FDA Approval to Market Cherry and Cinnamon Flavored Nicotine Lozenges
2. Perrigo Confirms That its Partner Synthon Has Filed for Generic Version of Xyzal(R) Solution and Announcement of Lawsuit by Sepracor/UCB
3. Perrigo Reports Record Third Quarter
4. Perrigo Company Announces Quarterly Dividend
5. Perrigo Announces FDA Approval for Sulfacetamide Sodium Topical Suspension USP, 10% (Lotion)
6. Perrigo Begins Shipments of Ibuprofen PM
7. Perrigo Reports Record Second Quarter Sales
8. Perrigo Company Announces Quarterly Dividend
9. Perrigo Company Appointed Generic Distributor by Medimetriks Pharmaceuticals
10. Perrigo Company Will Release Second Quarter Fiscal Year 2009 Results on February 3, 2009
11. Perrigo Company to Present at the 27th Annual JPMorgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... Junk-A-Car ( http://www.junkacar.com ), one of the ... to help drivers, especially those in and around the ... areas deal with the especially harsh winter weather that ... the country. , With the high number of reported ... crashed and junk cars, Junk-A-Car is voluntarily ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 Novatus, ... announced its Release v5.1 which provides customers with ... workflow options. , “As we continue to ... to provide more functionality and improved performance in ... Gambotz, CEO for Novatus. “With the enhancements that ...
(Date:11/28/2014)... November 28, 2014 Mirena lawsuits ... forward in New Jersey’s Bergen County Superior Court, ... litigation established there is quickly approaching 1,300, Bernstein ... November 18th shows 1,293 lawsuits now pending in ... that allege complications resulting from spontaneous migration of ...
(Date:11/28/2014)... Walder, one of South Florida’s top cosmetic dermatologists , ... that is designed to help her patients reduce unwanted fat ... has been praised by patients as being permanent, painless, and ... types of external fat reduction. , “If you can pinch ... According to Dr. Walder, Ultrashape works by targeting subcutaneous fat, ...
(Date:11/28/2014)... Dr. Paul Vitenas, one of the most awarded cosmetic ... Event for those in the area that would like to learn ... Glow will take place on December 11, 2014, from 6:00 p.m. ... of Houston at 4208 Richmond Ave. , “We want to ... come and celebrate the season with us on December 11, 2014 ...
Breaking Medicine News(10 mins):Health News:Junk-A-Car Expanding Service to Assist U.S. Car Owners That May be Affected by Severe Winter Storms 2Health News:Novatus Releases v5.1 with New Advanced Reporting Capabilities 2Health News:Nearly 1,300 Mirena Lawsuits Now Filed in Consolidated New Jersey Litigation, Bernstein Liebhard LLP Reports 2Health News:Nearly 1,300 Mirena Lawsuits Now Filed in Consolidated New Jersey Litigation, Bernstein Liebhard LLP Reports 3Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 2Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 3Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 3
... Prenatal Solution Key Factor in Decision for ... Jan. 8 Allscripts announced today that ... multi-specialty group practices in the Southeast United ... Health Record (EHR) to automate and connect ...
... Hospital have demonstrated a more effective treatment for ... antibiotics clindamycin and azithromycin, which kill bacteria by ... a standard first-line treatment with the "beta-lactam" antibiotic ... burst. , The finding is important ...
... 8 Allscripts-Misys Healthcare,Solutions, Inc., formerly Allscripts Healthcare ... financial results for the three and six,months ended ... (Logo: http://www.newscom.com/cgi-bin/prnh/20061005/ALLSCRIPTSLOGO-b ) , ... six months ended November 30, 2008,include results from ...
... 8 /PRNewswire-Asia/ -- Chindex International, Inc.,(Nasdaq: CHDX ... of Western healthcare products and services in the People,s ... the 2009 UBS Greater,China Conference, to be held in ... The 2009 UBS Greater China Conference will ...
... should be used when assessing traditional risk factors, experts say ... -- or "biomarkers" -- of inflammation may provide useful information ... research says. , "If you are very high or very ... said study lead author Dr. Vijay Nambi, a cardiologist at ...
... business continues to drive overall performanceDALLAS, Jan. 8 ... leader in hosted services for email encryption and e-prescribing, ... officer, Rick Spurr."We ended the year on a high ... the highest orders for the year in the fourth ...
Cached Medicine News:Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 2Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 3Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 4Health News:Study finds more effective treatment for pneumonia following influenza 2Health News:Study finds more effective treatment for pneumonia following influenza 3Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 2Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 3Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 4Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 5Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 6Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 7Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 8Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 9Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 10Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 11Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 12Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 13Health News:Chindex International Inc. Announces Participation in the 2009 UBS Greater China Conference 2Health News:Inflammation Markers May Help Predict Stroke Risk 2Health News:Inflammation Markers May Help Predict Stroke Risk 3Health News:Zix Corporation CEO Provides Corporate Update for Q4 and Year-End 2008 2Health News:Zix Corporation CEO Provides Corporate Update for Q4 and Year-End 2008 3Health News:Zix Corporation CEO Provides Corporate Update for Q4 and Year-End 2008 4
(Date:11/26/2014)... RADNOR, Pa. , Nov. 26, 2014 ... dedicated to the development of innovative transdermal synthetic cannabinoid ... the Piper Jaffray 26th Annual Healthcare Conference 2014. The ... the New York Palace in New York ... , will present at 4:50 pm on Tuesday, December ...
(Date:11/26/2014)... YORK and LONDON , ... of market intelligence, MarketResearch.com is pleased to announce the ... and Consultancy focusing on the active pharmaceutical ingredient (API) ... visit: http://www.marketresearch.com/land/publisher.asp?vendorid=4023&progid=86891 . In IQ4I,s ... – Forecast to 2020 , IQ4I ...
(Date:11/26/2014)... Reinforcing its commitment to enabling confident diagnosis ... PHG AEX: PHIA) today announced 510(k) clearance from ... IQon Spectral CT , presenting an entirely new ... a new dimension to Computed Tomography (CT) imaging, delivering ... based on their material content within a single scan. ...
Breaking Medicine Technology:Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3Philips receives FDA 510(k) clearance for IQon Spectral CT 2Philips receives FDA 510(k) clearance for IQon Spectral CT 3
... Tolerx, Inc. and GlaxoSmithKline (GSK) today ... an investigational humanized anti-CD3 monoclonal antibody, did not meet ... month 12 in patients with new-onset autoimmune type 1 ... data, no new or unexpected treatment-related safety concerns have ...
... MATEO, Calif., March 11, 2011 Sonitus Medical, Inc., ... non-surgical and removable hearing prosthetic to transmit sound via ... Mark certification for its SoundBite Hearing System. The company ... Assurance System Approval. This is the first European regulatory ...
Cached Medicine Technology:Tolerx and GlaxoSmithKline Announce Phase 3 Defend-1 Study of Otelixizumab in Type 1 Diabetes Did Not Meet Its Primary Endpoint 2Tolerx and GlaxoSmithKline Announce Phase 3 Defend-1 Study of Otelixizumab in Type 1 Diabetes Did Not Meet Its Primary Endpoint 3Tolerx and GlaxoSmithKline Announce Phase 3 Defend-1 Study of Otelixizumab in Type 1 Diabetes Did Not Meet Its Primary Endpoint 4Sonitus Medical Receives European CE Mark for SoundBite™ Hearing System 2
... Multimode Detectors provide unmatched value and ... and automation needs. Capable of performing ... the same instrument, the DTX Series ... can be integrated seamlessly with Beckman ...
... Screening (HTS), Analyst HT smoothes the ... sharing all the detection modalities and ... intensity, fluorescence polarization, time-resolved fluorescence, luminescence, ... into robotic environments, including those from ...
... the right features for assay development ... instrument control. Reduces the inevitable transfer ... HTS. Specifically developed to meet the ... AD delivers unparalleled detection performance for ...
... a flexible multifunction plate reader that offers ... fluorescence intensity, time-resolved fluorescence, high-perfomance luminescence and ... with injectors that deliver reagent at the ... cell assays can be performed easily and ...
Medicine Products: